Studies | EBMT

Top

Study type

Disease

Group

Type of transplant / Cell therapy

Text

Language

Adoption and Implementation of Oral Care Guidelines for the Prevention of Oral Mucositis in EBMT Centers: A Cross-sectional Survey Study of the EBMT Nurses Group

Closed Survey/Study

Nursing Research Committee

Type de traitement

Allogeneic - Related

Allogeneic - Unrelated

Allogeneic - Haploidentical

Investigateur principal

Carlotta Cadsky

CAR-T therapy outcomes in patients over 70 years old

Retrospective Studies

Complications Working Party (CWP)

Type de traitement

Investigateur principal

Guillaume Dachy

Non relapse mortality after CAR-T therapy

Retrospective Studies

Complications Working Party (CWP)

Type de traitement

Investigateur principal

Charlotte Graham

Outcomes of CAR T-Cell Therapy Versus Autologous HSCT in Patients with Large B-Cell Lymphoma in Complete Remission

Retrospective Studies

Non-Hodgkin’s Lymphoma (NHL)

Lymphoma Working Party (LWP)

Type de traitement

Investigateur principal

Dr. Remy DULERY

Allogeneic Stem Cell Transplant in Primary CNS Lymphoma

Retrospective Studies

Non-Hodgkin’s Lymphoma (NHL)

Lymphoma Working Party (LWP)

Type de traitement

Investigateur principal

Axicabtagene ciloleucel and lisocabtagene maraleucel as second-line treatment for patients with relapsed or refractory DLBCL - a real-world analysis of the lymphoma working party of the EBMT

Retrospective Studies

Non-Hodgkin’s Lymphoma (NHL)

Lymphoma Working Party (LWP)

Type de traitement

Investigateur principal

Dr. Anna Ossami SAIDY

Real World Experience of CAR-T in follicular lymphoma: a Lymphoma Working Party-EBMT study

Retrospective Studies

Non-Hodgkin’s Lymphoma (NHL)

Lymphoma Working Party (LWP)

Type de traitement

Investigateur principal

Dr. Leyre BENTO & Dr. Silvia MONTOTO

Non-interventional registry-based analysis in the use of Brentuximab Vedotin and/or Checkpoint inhibitors as bridge to autologous stem cell transplantation in Hodgkin lymphoma.

Non-interventional Prospective Studies

Hodgkin’s Disease (HD)

Lymphoma Working Party (LWP)

Type de traitement

Investigateur principal

Dr. Ali BAZARBACHI & Dr. Anna SUREDA

Autologous, Allogeneic Stem-Cell Transplantation and CART Cell therapy for Transformed Waldenström Macroglobulinemia (WM)/Lymphoplasmacytic Lymphoma (LPL) to High Grade NHL (HGNHL)

Retrospective Studies

Non-Hodgkin’s Lymphoma (NHL)

Lymphoma Working Party (LWP)

Type de traitement

Investigateur principal

Dr. Charalampia KYRIAKOU & Dr. Nour MOUKALLED

Non-T-Depleted Haploidentical Transplantation Compared to Allogeneic Transplantation From Matched Siblings or Unrelated Donors in Patients With Secondary AML in First Complete Remission: A Study From the ALWP/EBMT

Retrospective Studies

Acute Myeloid Leukaemia (AML)

Acute Leukemia Working Party (ALWP)

Type de traitement

Investigateur principal

Dr. Arnon Nagler

The impact of DNMT3A mutation on survival of AML patients receiving allotransplant in first remission depends on the karyotype and co-occurring mutations

Retrospective Studies

Acute Myeloid Leukaemia (AML)

Acute Leukemia Working Party (ALWP)

Type de traitement

Investigateur principal

Dr. Iman Abou Dalle

Graft-versus-host disease is not associated with reduced incidence of relapse following haploidentical stem cell transplantation with post-transplant cyclophosphamide for acute lymphoblastic leukaemia: A study on behalf of the Acute Leukaemia Working Party of European Society for Blood and Marrow Transplantation

Retrospective Studies

Acute Lymphatic Leukaemia (ALL)

Acute Leukemia Working Party (ALWP)

Type de traitement

Investigateur principal

Dr. Avichai Shimoni